Hangzhou Jeci Biochem Technology Co., Ltd. is located in Hangzhou, Zhejiang Province. We are committed to sales of active pharmaceutical ingredients and pharmaceutical intermediates, cooperative R & D, custom manufacturing, sales and service as well as import of pharmaceutical raw materials.
In China, we have a strong collaborative R&D team, working in depth with new drug research institutes and multiple custom processing plants. We have very good domestic sales channels and have long-term relationships with domestic pharmaceutical companies, including pharmaceutical applications, technology transfer, product supply, custom processing, and exclusive agents for multiple products in multiple regions. In addition, we also provides factory quality management system certification consulting services.
Internationally, we has long-term trade relations with India, Southeast Asia, South Korea, Japan and other markets, and provides products in the whole process of market and sales services. At the same time, we also provides API registration, consulting and sales channel expansion services for overseas companies in the Chinese market.
Our company's various chemical qualifications and certificates are complete, there are a variety of pharmaceutical intermediates and precursor chemicals, and most of the common dangerous goods business qualifications, and have complete import and export qualifications, the company's products are sold all over the world, and Acting for the import and export of various products such as hazardous chemicals.
The company is mainly engaged in wholesale, retail, biological products, pharmaceutical intermediates, first-class medical equipment, petroleum products, rubber products, plastic products, biological reagents, biochemical testing reagents and consumables, chemical reagents; pharmaceutical operations (operating with valid licenses) Import and export of goods and technology (except for projects prohibited by national laws and administrative regulations, and laws and administrative regulations stipulate that projects that restrict operations can only be operated after obtaining a permit). (Projects subject to approval according to law may be operated after approval by relevant departments)
Shanghai Pharmaceuticals
- Profile: A large pharmaceutical industry group covering R&D, production, sales, and other fields.
- Advantageous Product: Oseltamivir (Tamiflu), a core drug against influenza viruses. The company once obtained the patent authorization for oseltamivir from Roche Pharmaceuticals and is currently promoting the复产 (resumption of production) process of oseltamivir.
Yiling Pharmaceutical
- Profile: A national high-tech enterprise dedicated to the R&D, production, and sales of traditional Chinese medicine (TCM).
- Advantageous Product: Lianhua Qingwen Capsules/Granules, a star product listed in the national diagnostic and treatment protocols for influenza A, influenza B, and avian influenza 15 times. It was also included in the COVID-19 diagnosis and treatment protocols, demonstrating antiviral and anti-infective effects.
Xiangxue Pharmaceutical
- Profile: An important participant in formulating the national standard for antiviral oral liquids in China, and the first to innovate the fingerprint technology for antiviral oral liquids.
- Advantageous Product: Antiviral Oral Liquid, a national-level new drug with a pure natural plant formula. When combined with oseltamivir for influenza treatment, it helps enhance therapeutic effects.
Zhongsheng Pharmaceutical
- Profile: Founded in 1979, it is one of China's top 100 pharmaceutical industrial enterprises, with deep deployments in therapeutic areas such as ophthalmology, cardiovascular and cerebrovascular diseases, respiratory, and digestion.
- Advantageous Product: Letermovir tablets, China's first 3CL single-drug oral medication for anti-COVID-19 infection. It can rapidly reduce viral titers, shorten the negative conversion time, alleviate clinical symptoms, and show significant efficacy.
Puluo Pharmaceutical
- Profile: A major domestic producer of amantadine and rimantadine, which are used for influenza prevention and treatment and listed in the diagnostic and treatment protocols for human avian influenza.
- Advantageous Product: Amantadine and rimantadine. The company also has strong capabilities in pharmaceutical intermediate production, providing key raw materials for antiviral drug manufacturing.
Dongyang Pharmaceutical
- Profile: One of the leading enterprises in China's oseltamivir market.
- Advantageous Product: "Kewei," the phosphoric acid oseltamivir produced by the company, held a 64.8% market share in China's phosphoric acid oseltamivir market in 2023. It has the world's largest production base for phosphoric acid oseltamivir, with global-first cumulative production and shipment volumes within five years.
Borui Pharmaceutical
- Profile: A national high-tech enterprise with in-depth research in the fields of targeted and immunotherapy for tumors, as well as the treatment of fatty liver and diabetes.
- Advantageous Product: Obtained the generic authorization for Merck's COVID-19 oral drug Molnupiravir, laying out the global antiviral drug market.
Konqi Pharmaceutical
- Profile: Focused on pediatric medications, mainly producing antiviral oral liquids, ribavirin, etc.
- Advantageous Product: Antiviral Oral Liquid, specifically designed for children's constitutions, holding a certain market share in pediatric antiviral treatment.
Jinshi Asia Pharmaceutical
- Profile: Engages in producing "Kuai Ke Qing" antiviral oral liquid for influenza treatment, as well as cold medications like "Kuai Ke" compound paracetamol and amantadine capsules and "Xiao Kuai Ke" pediatric paracetamol and chlorpheniramine granules.
- Advantageous Product: "Kuai Ke Qing" Antiviral Oral Liquid, with high visibility in the cold and influenza treatment market.